Biotts
Founded 2018 · 18 employees on LinkedIn · 2 known investors
Biotts develops transdermal drug delivery products using its proprietary MTC-Y carrier system, a semisolid emulsion that transports both lipophilic and hydrophilic molecules up to 6,000 Da (including peptides and proteins) through the skin. The company creates its own transdermal drug products and licenses its technology and development expertise to the pharmaceutical industry.
Investors · 2
Frequently asked questions
- What does Biotts do?
- Biotts develops transdermal drug delivery products using its proprietary MTC-Y carrier system, a semisolid emulsion that transports both lipophilic and hydrophilic molecules up to 6,000 Da (including peptides and proteins) through the skin. The company creates its own transdermal drug products and licenses its technology and development expertise to the pharmaceutical industry.
- Who are Biotts's investors?
- Biotts's investors include Montis Capital, Montis VC.